These facilities are commissioned by Aurobindo's wholly own subsidiary: Lyfius Pharma Private Limited, Qule Pharma Private Limited, Eugia Steriles Private Limited and Auroactive Pharma Private Limited.
Grand opening of the joint venture between Evonik China and Shandong Vland Biotech in Qingdao, China
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths.
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
Through our research, we aim to ultimately provide new options for our customers to treat life-threatening infections in livestock
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
Subscribe To Our Newsletter & Stay Updated
